Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018–2023 - Takeaways - MDSpire

Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018–2023

  • By

  • Ahmed D Elnaiem

  • Anand B Chukka

  • Cynthia M So-Armah

  • MaryCatherine E Arbour

  • Chuan-Chin Huang

  • Daniel A Solomon

  • Lauren E Malishchak

  • Chase G Yarbrough

  • June 13, 2025

  • 0 min

Share

  • 1

    HCV disproportionately affects racial minorities and socially disadvantaged groups in the U.S., despite effective direct-acting antiviral therapies.

  • 2

    In a study of 4345 individuals, only 26.5% were prescribed HCV treatment, highlighting significant treatment disparities.

  • 3

    Black individuals, those experiencing homelessness, and individuals with Medicaid or no insurance were less likely to receive HCV treatment.

  • 4

    Individuals with mental health diagnoses were more likely to initiate HCV treatment compared to those without such diagnoses.

  • 5

    Despite progressive policies, treatment disparities persist, indicating that policy reform alone may not ensure equitable HCV elimination.

Original Source(s)

Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018–2023

  • by Ahmed D Elnaiem, Anand B Chukka, Cynthia M So-Armah, MaryCatherine E Arbour, Chuan-Chin Huang, Daniel A Solomon, Lauren E Malishchak, Chase G Yarbrough

  • June 13, 2025

Related Content

HCV Core Antigen Diagnostic Performance for Acute/Recent HCV Infection in People With HIV-1: A Systematic Review and Meta-Analysis

Assessment of the occurrence and factors influencing hepatitis B, hepatitis C, and liver damage in individuals with HIV undergoing antiretroviral treatment in Ghana's Upper East Region

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.